ArticleJournal of racial and ethnic health disparities2026
Reassessing the Racial Survival Disparity in Renal Medullary Carcinoma: The Roles of Race-Ethnicity Misclassification and Access to Surgery.
Article in Journal of racial and ethnic health disparities, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal medullary carcinoma (RMC) is a rare, aggressive kidney cancer affecting young Black patients. A previous analysis of the Surveillance, Epidemiology and End Results (SEER) database reported an approximately five-fold higher mortality among Black patients. We reassessed whether this disparity is reproducible and examined the roles of race-ethnicity misclassification and access to surgery.
methodsWe identified RMC cases (histology code 8510/3) in the SEER database (2000-2022). Overall survival was modelled with multivariable Cox regression and cancer-specific survival with Fine-Gray competing-risks regression. The SEER race code was reclassified into the National Institutes of Health five-class race-ethnicity scheme, and access to surgery was examined with inverse-probability-of-treatment weighting. Robustness was assessed across six analytic approaches and a leave-one-cell-out diagnostic.
resultsOf 148 patients, 147 were analysed (median age 27 years; 79% Black; median overall survival 9 months). The five-fold difference was not reproduced: the adjusted hazard ratio (HR) for Black versus White race was 1.17 (95% confidence interval [CI] 0.71-1.93) and the Fine-Gray subdistribution HR was 1.01 (0.58-1.76), with every CI spanning 1.0. Of 29 patients coded 'White', 17 (59%) were Hispanic and only 12 were non-Hispanic White. An apparent sex×race interaction collapsed when any single cell was removed (P = 1.0). Surgery was associated with longer survival, but this apparent benefit is likely confounded by indication and should not be interpreted as causal.
conclusionsThe previously reported racial disparity in RMC was not reproducible and is better explained by race-ethnicity misclassification and access to treatment than by tumour biology. These findings caution against crude Black-White comparisons in small registry cohorts.
Indexed as
Identifiers
42671782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.